As we continue to learn more about the molecular mechanisms underlying the pathogenesis of AD, novel therapeutic targets will be identified, which, when targeted as well, might enhance the effectiveness of current tau and Aβ therapeutics. The gene discussed is MAPT; the disease is Alzheimer disease.